Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Inbrija in Smokers and Non-Smokers
NCT02633839Phase 1Completed
- Sponsor
- Acorda Therapeutics
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label trial of levodopa inhalation powder in Parkinson's disease (PD) (2 arms), sponsored by Acorda Therapeutics. Primary endpoints: Maximum observed plasma drug concentration, Time to maximum observed plasma drug concentration and 1 more. Started Dec 2015; status: completed.
02
Drugs
levodopa inhalation powder
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02633839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633839.